24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
Spotlight
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
BioProtect
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
19:12
Wix turns to $2 billion buyback to shore up confidence after stock slump
17:30
WSC Sports acquires UK sponsorship platform Partnerbrite in $10 million deal
16:48
Backed by SentinelOne, Mesh Security raises $12 million Series A to unify fragmented enterprise cyber tools
16:33
After a near reset, Adaptive6 secures $28 million Series A to tackle cloud waste
More stories
Buzz
Most popular
Daily
Weekly
1
Intel employees receive 1.8-month bonus in rebound from last year’s cut
2
“SaaS is dying as a business category”
3
Israel orders $183 million in air-to-ground bombs from Elbit
4
“We built monday in four hours using our system”
5
Mobile gaming’s era of easy money is over
More news
BioProtect
3 stories about BioProtect
Is it time to reconsider PSA tests for Prostate Cancer?
01.09.22
|
Itay Barnea
“The treating physician should determine what is best for the patient based on his unique age, family history, health, lifestyle, race, ethnic background, and other factors,” writes Itay Barnea, CEO of BioProtect
Which Israeli cancer treatment company raised $57 million and who is making money off double chins?
22.09.20
|
CTech
CTech Daily Roundup: Medtronic invests $4.5 million as part of BioProtect $25 million series D
Medtronic invests $4.5 million as part of BioProtect $25 million series D
22.09.20
|
Meir Orbach
Proceeds of the round will finance the ongoing multicenter FDA clinical trial of BioProtect's lead product, the ProSpace balloon spacer, which protects prostate cancer patients undergoing radiation therapy